• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SelectQuote, Inc. Reports First Quarter of Fiscal Year 2026 Results

    11/6/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance
    Get the next $SLQT alert in real time by email

    First Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights

    • Revenue of $328.8 million
    • Net loss of $30.5 million
    • Adjusted EBITDA* of $(32.1) million

    First Quarter Fiscal Year 2026 – Segment Highlights

    Senior

    • Revenue of $59.0 million
    • Adjusted EBITDA of $(21.0) million
    • Approved Medicare Advantage policies of 62,510

    Healthcare Services

    • Revenue of $221.4 million
    • Adjusted EBITDA of $7.2 million
    • 106,914 SelectRx members

    Life

    • Revenue of $46.6 million
    • Adjusted EBITDA of $5.6 million

    SelectQuote, Inc. (NYSE:SLQT) reported consolidated revenue for the first quarter of fiscal year 2026 of $328.8 million compared to consolidated revenue for the first quarter of fiscal year 2025 of $292.3 million. Consolidated net loss for the first quarter of fiscal year 2026 was $30.5 million compared to consolidated net loss for the first quarter of fiscal year 2025 of $44.5 million. Finally, consolidated Adjusted EBITDA* for the first quarter of fiscal year 2026 was $(32.1) million compared to consolidated Adjusted EBITDA* for the first quarter of fiscal year 2025 of $(1.7) million.

    Tim Danker, SelectQuote Chief Executive Officer, remarked "The strength of our integrated healthcare model was exhibited again in our fiscal first quarter. Early work to prepare for new eligibility parameters in this year's Medicare Advantage special election period was evident in our Senior business. We successfully reallocated resources and agents for the expected decline in volume and, as a result, performed well in the quarter and more importantly positioned our Senior business for another strong season. We firmly maintain our view that SelectQuote's Medicare Advantage business has durable competitive advantage and flexibility to drive strong results in a range of environments. While the past three years have presented different challenges and opportunities, SelectQuote has excelled and validated our visibility and confidence in the generation of return and cash flow in our Senior distribution business."

    Mr. Danker added, "Our Healthcare Services business also continues to perform well, serving over 100,000 SelectRx members with convenient drug delivery that drives improved health outcomes. Our value-added prescription drug delivery and patient adherence pharmacy offers real, differentiated value to both the patient and the insurance payor. When our data and service approach provides better care, patients win, and do so at more efficient cost to the overall healthcare system. We continue to see SelectQuote as a healthcare services ecosystem that can create system-wide value in a range of use cases. In this quarter, SelectQuote generated a revenue to customer acquisition cost (CAC) ratio of 6.4x, which is an all-time high and nearly 40% higher than it was a year ago. While profitability is our ultimate north star, we view this metric as a strong indicator on how we are helping our customers with more and more, each and every year."

    Mr. Danker concluded, "At this time, we are not changing our fiscal 2026 financial outlook of $1.65 to $1.75 billion in revenue and $120 to $150 million in Adjusted EBITDA*. In Healthcare Services, a temporary reimbursement rate headwind in our SelectRx business impacted this quarter and we expect will drive adjusted EBITDA around breakeven for the segment in the fiscal second quarter. SelectQuote and our PBM partners are committed to the significant value provided to patients of SelectRx, and we expect Healthcare Services to exit fiscal 2026 at an Adjusted EBITDA run rate in the $40 to $50 million range."

    * See "Non-GAAP Financial Measures" below.

    Segment Results

    We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and adjusted EBITDA. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is our segment profit measure to evaluate the operating performance of our business. We define Adjusted EBITDA as net income (loss) before income tax expense (benefit) plus interest expense, depreciation and amortization, changes in fair value of warrant liabilities, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenue.

    Senior

    Financial Results

    The following table provides the financial results for the Senior segment for the periods presented:

     

     

    Three Months Ended September 30,

     

     

    (in thousands)

     

    2025

     

    2024

     

    % Change

    Revenue

     

    $

    58,996

     

     

    $

    92,908

     

     

    (37

    )%

    Adjusted EBITDA

     

     

    (21,036

    )

     

     

    7,724

     

     

    (372

    )%

    Adjusted EBITDA Margin

     

     

    (36

    )%

     

     

    8

    %

     

     

    Operating Metrics

    Submitted Policies

    Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

    The following table shows the number of submitted policies for the periods presented:

     

     

    Three Months Ended September 30,

     

     

     

    2025

     

    2024

     

    % Change

    Medicare Advantage

     

    70,240

     

    102,281

     

    (31

    )%

    All other (1)

     

    17,174

     

    16,256

     

    6

    %

    Total

     

    87,414

     

    118,537

     

    (26

    )%

    (1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

    Approved Policies

    Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

    The following table shows the number of approved policies for the periods presented:

     

     

    Three Months Ended September 30,

     

     

     

    2025

     

    2024

     

    % Change

    Medicare Advantage

     

    62,510

     

    91,680

     

    (32

    )%

    All other (1)

     

    13,876

     

    12,979

     

    7

    %

    Total

     

    76,386

     

    104,659

     

    (27

    )%

    (1) Represents the approved policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

    Lifetime Value of Commissions per Approved Policy

    Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

    The following table shows the lifetime value of commissions per approved policy for the periods presented:

     

     

    Three Months Ended September 30,

     

     

    (dollars per policy):

     

    2025

     

    2024

     

    % Change

    Medicare Advantage

     

    $

    769

     

    $

    812

     

    (5

    )%

    All other(1)

     

     

    133

     

     

    165

     

    (19

    )%

    (1) Represents the weighted average LTV per approved policy.

    Healthcare Services

    Financial Results

    The following table provides the financial results for the Healthcare Services segment for the periods presented:

     

     

    Three Months Ended September 30,

     

     

    (in thousands)

     

    2025

     

    2024

     

    % Change

    Revenue

     

    $

    221,351

     

     

    $

    155,739

     

     

    42

    %

    Adjusted EBITDA

     

     

    7,212

     

     

     

    4,878

     

     

    48

    %

    Adjusted EBITDA Margin

     

     

    3

    %

     

     

    3

    %

     

     

    Operating Metrics

    Members

    The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

    The following table shows the total number of SelectRx members as of the periods presented:

     

     

    September 30, 2025

     

    September 30, 2024

    Total SelectRx Members

     

    106,914

     

    86,521

    The total number of SelectRx members increased by 24% as of September 30, 2025, compared to September 30, 2024, due to our strategy to grow SelectRx membership.

    The following table shows the average prescriptions shipped per day for the periods presented:

     

     

    Three Months Ended September 30,

     

     

    2025

     

    2024

    Prescriptions Per Day

     

    31,378

     

    24,998

    Combined Senior and Healthcare Services - Consumer Per Unit Economics

    Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

    The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents' core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company's reassessment of its cohorts' transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost ("CAC") multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

    The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

     

     

    Twelve Months Ended September 30,

    (dollars per approved policy):

     

    2025

     

    2024

    MA and MS approved policies

     

     

    565,529

     

     

     

    621,040

     

    MA and MS commission per MA / MS policy

     

    $

    884

     

     

    $

    919

     

    Other commission per MA/MS policy

     

     

    13

     

     

     

    12

     

    Pharmacy revenue per MA/MS policy

     

     

    1,405

     

     

     

    842

     

    Other revenue per MA/MS policy

     

     

    129

     

     

     

    152

     

    Total revenue per MA / MS policy

     

     

    2,431

     

     

     

    1,925

     

    Total operating expenses per MA / MS policy

     

     

    (2,147

    )

     

     

    (1,626

    )

    Adjusted EBITDA per MA/MS policy

     

    $

    284

     

     

    $

    299

     

    Adjusted EBITDA Margin per MA/MS policy

     

     

    12

    %

     

     

    16

    %

    Revenue / CAC multiple

     

    6.4X

     

    4.6X

    Total revenue per MA/MS policy increased 26% for the twelve months ended September 30, 2025, compared to the twelve months ended September 30, 2024, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 32% for the twelve months ended September 30, 2025, compared to the twelve months ended September 30, 2024, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

    Life

    Financial Results

    The following table provides the financial results for the Life segment for the periods presented:

     

     

    Three Months Ended September 30,

     

     

    (in thousands)

     

    2025

     

    2024

     

    % Change

    Revenue

     

    $

    46,647

     

     

    $

    39,290

     

     

    19

    %

    Adjusted EBITDA

     

     

    5,570

     

     

     

    5,960

     

     

    (7

    )%

    Adjusted EBITDA Margin

     

     

    12

    %

     

     

    15

    %

     

     

    Operating Metrics

    Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

    The following table shows term and final expense premiums for the periods presented:

     

     

    Three Months Ended September 30,

     

     

    (in thousands)

     

    2025

     

    2024

     

    % Change

    Term Premiums

     

    $

    19,443

     

    $

    15,218

     

    28

    %

    Final Expense Premiums

     

     

    29,429

     

     

    24,473

     

    20

    %

    Total

     

    $

    48,872

     

    $

    39,691

     

    23

    %

    Earnings Conference Call

    SelectQuote, Inc. will host a conference call with the investment community on November 6, 2025 beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://registrations.events/direct/Q4I4247512. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

    Non-GAAP Financial Measures

    This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income (loss) plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss). We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

    A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP measure, net income (loss), is presented below on page 14. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results.

    Forward Looking Statements

    This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continue," "will," "anticipate," "seek," "estimate," "intend," "plan," "projection," "would" and "outlook," or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

    There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation and tariffs; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; existing or potential litigation and other legal proceedings or inquiries, including the Department of Justice action alleging violations of the federal False Claims Act; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers' approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, contractual reimbursement rates, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

    About SelectQuote:

    Founded in 1985, SelectQuote (NYSE:SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

    With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (In thousands)

       

     

     

    September 30, 2025

     

    June 30, 2025

    ASSETS

     

     

     

     

    CURRENT ASSETS:

     

     

     

     

    Cash, cash equivalents, and restricted cash

     

    $

    14,461

     

     

    $

    35,733

     

    Accounts receivable, net of allowances of $11.6 million and $11.8 million, respectively

     

     

    104,485

     

     

     

    151,388

     

    Commissions receivable-current

     

     

    193,395

     

     

     

    132,077

     

    Other current assets

     

     

    19,622

     

     

     

    21,844

     

    Total current assets

     

     

    331,963

     

     

     

    341,042

     

    COMMISSIONS RECEIVABLE—Net

     

     

    786,434

     

     

     

    818,751

     

    PROPERTY AND EQUIPMENT—Net

     

     

    14,377

     

     

     

    14,577

     

    SOFTWARE—Net

     

     

    15,782

     

     

     

    15,060

     

    OPERATING LEASE RIGHT-OF-USE ASSETS

     

     

    23,615

     

     

     

    24,635

     

    INTANGIBLE ASSETS—Net

     

     

    1,689

     

     

     

    1,973

     

    GOODWILL

     

     

    29,438

     

     

     

    29,438

     

    OTHER ASSETS

     

     

    3,678

     

     

     

    3,880

     

    TOTAL ASSETS

     

    $

    1,206,976

     

     

    $

    1,249,356

     

     

     

     

     

     

    LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY

     

     

     

     

    CURRENT LIABILITIES:

     

     

     

     

    Accounts payable

     

    $

    34,567

     

     

    $

    59,205

     

    Accrued expenses

     

     

    50,001

     

     

     

    13,856

     

    Accrued compensation and benefits

     

     

    49,816

     

     

     

    58,788

     

    Operating lease liabilities—current

     

     

    4,886

     

     

     

    4,820

     

    Current portion of long-term debt

     

     

    68,337

     

     

     

    68,523

     

    Contract liabilities

     

     

    1,971

     

     

     

    698

     

    Other current liabilities

     

     

    6,152

     

     

     

    7,020

     

    Total current liabilities

     

     

    215,730

     

     

     

    212,910

     

    LONG-TERM DEBT, NET—less current portion

     

     

    324,812

     

     

     

    316,589

     

    DEFERRED INCOME TAXES

     

     

    28,703

     

     

     

    37,872

     

    OPERATING LEASE LIABILITIES

     

     

    24,812

     

     

     

    25,982

     

    OTHER LIABILITIES

     

     

    65,993

     

     

     

    80,485

     

    Total liabilities

     

     

    660,050

     

     

     

    673,838

     

     

     

     

     

     

    COMMITMENTS AND CONTINGENCIES

     

     

     

     

    PREFERRED STOCK:

     

     

     

     

    Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares issued and outstanding as of September 30, 2025 and June 30, 2025, respectively, current liquidation preference of $380.4 million and $367.1 million as of September 30, 2025 and June 30, 2025.

     

     

    241,856

     

     

     

    224,374

     

    SHAREHOLDERS' EQUITY:

     

     

     

     

    Common stock, $0.01 par value

     

     

    1,759

     

     

     

    1,728

     

    Additional paid-in capital

     

     

    555,959

     

     

     

    571,605

     

    Accumulated deficit

     

     

    (252,648

    )

     

     

    (222,189

    )

    Total shareholders' equity

     

     

    305,070

     

     

     

    351,144

     

    TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY

     

    $

    1,206,976

     

     

    $

    1,249,356

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

    (Unaudited)

    (In thousands)

     

     

     

    Three Months Ended September 30,

     

     

    2025

     

    2024

    REVENUE:

     

     

     

     

    Commissions and other services

     

    $

    110,267

     

     

    $

    139,380

     

    Pharmacy

     

     

    218,544

     

     

     

    152,883

     

    Total revenue

     

     

    328,811

     

     

     

    292,263

     

     

     

     

     

     

    OPERATING COSTS AND EXPENSES:

     

     

     

     

    Cost of commissions and other services revenue

     

     

    69,101

     

     

     

    65,733

     

    Cost of goods sold—pharmacy revenue

     

     

    192,779

     

     

     

    129,524

     

    Marketing and advertising

     

     

    61,947

     

     

     

    63,764

     

    Selling, general, and administrative

     

     

    35,819

     

     

     

    36,145

     

    Technical development

     

     

    9,911

     

     

     

    9,074

     

    Total operating costs and expenses

     

     

    369,557

     

     

     

    304,240

     

     

     

     

     

     

    LOSS FROM OPERATIONS

     

     

    (40,746

    )

     

     

    (11,977

    )

     

     

     

     

     

    INTEREST EXPENSE, NET

     

     

    (11,808

    )

     

     

    (23,031

    )

    CHANGE IN FAIR VALUE OF WARRANTS

     

     

    15,036

     

     

     

    —

     

    OTHER EXPENSE, NET

     

     

    (145

    )

     

     

    (12

    )

    LOSS BEFORE INCOME TAX EXPENSE (BENEFIT)

     

     

    (37,663

    )

     

     

    (35,020

    )

    INCOME TAX EXPENSE (BENEFIT)

     

     

    (7,204

    )

     

     

    9,526

     

     

     

     

     

     

    NET LOSS

     

    $

    (30,459

    )

     

    $

    (44,546

    )

    Senior Non-Convertible Preferred Stock accumulated dividends and accretion

     

     

    (17,482

    )

     

     

    —

     

    NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

     

    $

    (47,941

    )

     

    $

    (44,546

    )

     

     

     

     

     

    NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:

     

     

     

     

    Basic

     

    $

    (0.26

    )

     

    $

    (0.26

    )

    Diluted

     

    $

    (0.26

    )

     

    $

    (0.26

    )

     

     

     

     

     

    WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:

     

     

     

     

    Basic

     

     

    185,816

     

     

     

    170,431

     

    Diluted

     

     

    185,816

     

     

     

    170,431

     

     

     

     

     

     

    OTHER COMPREHENSIVE LOSS, NET OF TAX:

     

     

     

     

    Unrealized loss, net of related tax benefit of $0.0 million and $0.0 million

     

     

    —

     

     

     

    (39

    )

    Amount reclassified into earnings, net of related tax benefit of $0.0 million and $1.0 million

     

     

    —

     

     

     

    (2,746

    )

    OTHER COMPREHENSIVE LOSS

     

     

    —

     

     

     

    (2,785

    )

    COMPREHENSIVE LOSS

     

    $

    (30,459

    )

     

    $

    (47,331

    )

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited)

    (In thousands)

     

     

     

    Three Months Ended September 30,

     

     

    2025

     

    2024

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

     

    Net loss

     

    $

    (30,459

    )

     

    $

    (44,546

    )

    Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities:

     

     

     

     

    Depreciation and amortization

     

     

    4,300

     

     

     

    5,599

     

    Loss on disposal of property, equipment, and software

     

     

    —

     

     

     

    68

     

    Share-based compensation expense

     

     

    4,327

     

     

     

    3,846

     

    Deferred income taxes

     

     

    (9,168

    )

     

     

    9,526

     

    Amortization of debt issuance costs and debt discount

     

     

    1,184

     

     

     

    1,064

     

    Accrued interest payable in kind

     

     

    —

     

     

     

    5,289

     

    Change in fair value of warrants

     

     

    (15,036

    )

     

     

    —

     

    Non-cash lease expense

     

     

    1,021

     

     

     

    903

     

    Changes in operating assets and liabilities:

     

     

     

     

    Accounts receivable, net

     

     

    46,902

     

     

     

    50,501

     

    Commissions receivable

     

     

    (29,001

    )

     

     

    (38,466

    )

    Other assets

     

     

    2,371

     

     

     

    (3,516

    )

    Accounts payable and accrued expenses

     

     

    11,395

     

     

     

    12,761

     

    Operating lease liabilities

     

     

    (1,105

    )

     

     

    (1,127

    )

    Other liabilities

     

     

    (8,354

    )

     

     

    (18,512

    )

    Net cash used in operating activities

     

     

    (21,623

    )

     

     

    (16,610

    )

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

     

    Purchases of property and equipment

     

     

    (1,058

    )

     

     

    (442

    )

    Purchases of software and capitalized software development costs

     

     

    (2,926

    )

     

     

    (2,132

    )

    Net cash used in investing activities

     

     

    (3,984

    )

     

     

    (2,574

    )

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

     

    Proceeds from revolving credit facility

     

     

    80,000

     

     

     

    —

     

    Payments on revolving credit facility

     

     

    (65,000

    )

     

     

    —

     

    Payments on Term Loans

     

     

    (3,573

    )

     

     

    (8,471

    )

    Payments on ABS Notes

     

     

    (4,543

    )

     

     

    —

     

    Payments on other debt

     

     

    (112

    )

     

     

    (30

    )

    Proceeds from common stock options exercised and employee stock purchase plan

     

     

    —

     

     

     

    38

     

    Payments of tax withholdings related to net share settlement of equity awards

     

     

    (2,460

    )

     

     

    (3,915

    )

    Payments of debt issuance costs

     

     

    (72

    )

     

     

    (684

    )

    Net cash provided by (used in) financing activities

     

     

    4,240

     

     

     

    (13,062

    )

    NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

     

     

    (21,367

    )

     

     

    (32,246

    )

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period

     

     

    37,066

     

     

     

    42,690

     

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH—End of period

     

    $

    15,699

     

     

    $

    10,444

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Adjusted EBITDA to Loss before income tax expense (benefit) Reconciliation by Segment

    (Unaudited)

       

     

     

    Three Months Ended September 30, 2025

    (in thousands)

     

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

     

    $

    58,996

     

     

    $

    221,351

     

     

    $

    46,647

     

     

    $

    326,994

     

    Less:

     

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

     

    (41,897

    )

     

     

    (6,301

    )

     

     

    (17,979

    )

     

     

    Cost of goods sold - pharmacy revenue

     

     

    —

     

     

     

    (191,398

    )

     

     

    —

     

     

     

    Marketing expense

     

     

    (37,630

    )

     

     

    (2,389

    )

     

     

    (22,760

    )

     

     

    Technical development

     

     

    —

     

     

     

    (438

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

     

    (505

    )

     

     

    (13,613

    )

     

     

    (338

    )

     

     

    Adjusted Segment EBITDA

     

    $

    (21,036

    )

     

    $

    7,212

     

     

    $

    5,570

     

     

    $

    (8,254

    )

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

     

    1,888

     

    Corporate

     

     

     

     

     

     

     

     

    (25,713

    )

    Share-based compensation expense

     

     

     

     

     

     

     

     

    (4,327

    )

    Transaction costs

     

     

     

     

     

     

     

     

    (185

    )

    Depreciation and amortization

     

     

     

     

     

     

     

     

    (4,300

    )

    Change in fair value of warrants

     

     

     

     

     

     

     

     

    15,036

     

    Interest expense, net

     

     

     

     

     

     

     

     

    (11,808

    )

    Loss before income tax expense (benefit)

     

     

     

     

     

     

     

    $

    (37,663

    )

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Adjusted EBITDA to Loss before income tax expense (benefit) Reconciliation by Segment

    (Unaudited)

     

     

     

    Three Months Ended September 30, 2024

    (in thousands)

     

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

     

    $

    92,908

     

     

    $

    155,739

     

     

    $

    39,290

     

     

    $

    287,937

     

    Less:

     

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

     

    (41,127

    )

     

     

    (5,879

    )

     

     

    (14,572

    )

     

     

    Cost of goods sold - pharmacy revenue

     

     

    —

     

     

     

    (128,366

    )

     

     

    —

     

     

     

    Marketing expense

     

     

    (43,378

    )

     

     

    (2,247

    )

     

     

    (18,496

    )

     

     

    Technical development

     

     

    —

     

     

     

    (608

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

     

    (679

    )

     

     

    (13,761

    )

     

     

    (262

    )

     

     

    Adjusted Segment EBITDA

     

    $

    7,724

     

     

    $

    4,878

     

     

    $

    5,960

     

     

    $

    18,562

     

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

     

    3,797

     

    Corporate

     

     

     

     

     

     

     

     

    (24,042

    )

    Share-based compensation expense

     

     

     

     

     

     

     

     

    (3,846

    )

    Transaction costs

     

     

     

     

     

     

     

     

    (826

    )

    Depreciation and amortization

     

     

     

     

     

     

     

     

    (5,599

    )

    Loss on disposal of property, equipment, and software, net

     

     

     

     

     

     

     

     

    (35

    )

    Interest expense, net

     

     

     

     

     

     

     

     

    (23,031

    )

    Loss before income tax expense (benefit)

     

     

     

     

     

     

     

    $

    (35,020

    )

    RECONCILIATION OF NON-GAAP MEASURE

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Reconciliation of Net loss to Adjusted EBITDA

    (Unaudited)

     

     

     

    Three Months Ended September 30,

    (in thousands)

     

    2025

     

    2024

    Net loss

     

    $

    (30,459

    )

     

    $

    (44,546

    )

    Share-based compensation expense

     

     

    4,327

     

     

     

    3,846

     

    Transaction costs

     

     

    185

     

     

     

    826

     

    Depreciation and amortization

     

     

    4,300

     

     

     

    5,599

     

    Loss on disposal of property, equipment, and software, net

     

     

    —

     

     

     

    35

     

    Change in fair value of warrants

     

     

    (15,036

    )

     

     

    —

     

    Interest expense, net

     

     

    11,808

     

     

     

    23,031

     

    Income tax expense (benefit)

     

     

    (7,204

    )

     

     

    9,526

     

    Adjusted EBITDA

     

    $

    (32,079

    )

     

    $

    (1,683

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251106390529/en/

    Investor Relations:

    Sloan Bohlen

    877-678-4083

    [email protected]

    Media:

    Matt Gunter

    913-286-4931

    [email protected]

    Get the next $SLQT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLQT

    DatePrice TargetRatingAnalyst
    5/21/2025$2.75Hold
    Jefferies
    9/30/2024$4.50Buy
    Craig Hallum
    2/29/2024$5.00Outperform
    Noble Capital Markets
    4/1/2022$4.00Neutral
    Credit Suisse
    2/8/2022$9.00 → $5.00Equal Weight
    Barclays
    2/8/2022$13.00 → $3.00Sector Perform
    RBC Capital
    2/8/2022$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    2/8/2022$14.00 → $4.00Outperform → Neutral
    Credit Suisse
    More analyst ratings

    $SLQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Clement Ryan Moore covered exercise/tax liability with 62,002 shares and converted options into 211,240 shares, increasing direct ownership by 96% to 304,705 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    8/5/25 9:24:57 PM ET
    $SLQT
    Specialty Insurers
    Finance

    President, SelectQuote Senior Matthews Joshua Brandon converted options into 144,321 shares, increasing direct ownership by 30% to 625,944 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    8/5/25 9:24:49 PM ET
    $SLQT
    Specialty Insurers
    Finance

    Chief Accounting Officer Fisher Stephanie D. converted options into 59,651 shares and covered exercise/tax liability with 25,266 shares, increasing direct ownership by 49% to 104,582 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    8/5/25 9:24:35 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SelectQuote, Inc. Reports First Quarter of Fiscal Year 2026 Results

    First Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Revenue of $328.8 million Net loss of $30.5 million Adjusted EBITDA* of $(32.1) million First Quarter Fiscal Year 2026 – Segment Highlights Senior Revenue of $59.0 million Adjusted EBITDA of $(21.0) million Approved Medicare Advantage policies of 62,510 Healthcare Services Revenue of $221.4 million Adjusted EBITDA of $7.2 million 106,914 SelectRx members Life Revenue of $46.6 million Adjusted EBITDA of $5.6 million SelectQuote, Inc. (NYSE:SLQT) reported consolidated revenue for the first quarter of fiscal year 2026 of $328.8 million compared to consolidated revenue for the first quarter of fi

    11/6/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote to Release Fiscal First Quarter 2026 Earnings on November 6

    SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its first quarter 2026 financial results before market open on Thursday, November 6, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (November 6, 2025) at 8:30 am ET to discuss the results. To register for this conference call, please use this link: https://registrations.events/direct/Q4I4247512. After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry.

    10/23/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote's Healthcare Select Research Uncovers Critical Gaps in Care, Highlighting Urgent Need for Personalized Healthcare Solutions

    Nearly 70% of Served Population Face Limited Access to a Local Pharmacy SelectQuote, Inc. (NYSE:SLQT) (the "Company"), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today released a new research brief offering in-depth insights into the complex medical and social needs of the population it serves. The findings from tens of thousands of patient health needs assessments gathered by the Company's Healthcare Select division highlight significant challenges across chronic care management, medication access, and financial security, underscoring the critical industry need for personalized, integrated healthcare solutions. Key

    10/15/25 4:15:00 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Devine Denise L bought $14,460 worth of shares (4,000 units at $3.62), increasing direct ownership by 1% to 318,583 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    3/19/25 4:54:26 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form 4: Matthews Joshua Brandon bought $113,295 worth of shares (97,500 units at $1.16), increasing direct ownership by 32% to 400,937 units

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    9/18/23 6:29:01 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form 4: Grant William Thomas Iii bought $179,250 worth of shares (150,000 units at $1.20), increasing direct ownership by 9% to 1,913,851 units

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    9/18/23 6:28:20 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    SEC Filings

    View All

    SEC Form S-8 filed by SelectQuote Inc.

    S-8 - SelectQuote, Inc. (0001794783) (Filer)

    11/7/25 4:35:56 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form 10-Q filed by SelectQuote Inc.

    10-Q - SelectQuote, Inc. (0001794783) (Filer)

    11/6/25 4:02:58 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SelectQuote, Inc. (0001794783) (Filer)

    11/6/25 7:33:01 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on SelectQuote with a new price target

    Jefferies initiated coverage of SelectQuote with a rating of Hold and set a new price target of $2.75

    5/21/25 8:59:27 AM ET
    $SLQT
    Specialty Insurers
    Finance

    Craig Hallum initiated coverage on SelectQuote with a new price target

    Craig Hallum initiated coverage of SelectQuote with a rating of Buy and set a new price target of $4.50

    9/30/24 8:47:10 AM ET
    $SLQT
    Specialty Insurers
    Finance

    Noble Capital Markets initiated coverage on SelectQuote with a new price target

    Noble Capital Markets initiated coverage of SelectQuote with a rating of Outperform and set a new price target of $5.00

    2/29/24 8:29:44 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Leadership Updates

    Live Leadership Updates

    View All

    SelectQuote Names Ryan Clement as Chief Financial Officer

    Clement has served as Interim CFO since May 2022 SelectQuote, Inc. (NYSE:SLQT) today announced that the Board of Directors appointed Ryan Clement, SVP of Financial Planning & Analysis, to serve as the company's Chief Financial Officer. Clement was named interim CFO in May 2022. CEO Tim Danker commented, "Over the last year, Ryan has excelled as our Interim CFO and has demonstrated both the financial acumen and leadership qualities we are looking for in the company's next permanent CFO. Ryan has played a critical role in our strategic redesign that has vastly improved SelectQuote's operating results and financial stability and positions the company to execute on our objectives in the futur

    2/22/23 8:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Financials

    Live finance-specific insights

    View All

    SelectQuote, Inc. Reports First Quarter of Fiscal Year 2026 Results

    First Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Revenue of $328.8 million Net loss of $30.5 million Adjusted EBITDA* of $(32.1) million First Quarter Fiscal Year 2026 – Segment Highlights Senior Revenue of $59.0 million Adjusted EBITDA of $(21.0) million Approved Medicare Advantage policies of 62,510 Healthcare Services Revenue of $221.4 million Adjusted EBITDA of $7.2 million 106,914 SelectRx members Life Revenue of $46.6 million Adjusted EBITDA of $5.6 million SelectQuote, Inc. (NYSE:SLQT) reported consolidated revenue for the first quarter of fiscal year 2026 of $328.8 million compared to consolidated revenue for the first quarter of fi

    11/6/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote to Release Fiscal First Quarter 2026 Earnings on November 6

    SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its first quarter 2026 financial results before market open on Thursday, November 6, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (November 6, 2025) at 8:30 am ET to discuss the results. To register for this conference call, please use this link: https://registrations.events/direct/Q4I4247512. After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry.

    10/23/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2025 Results

    Fourth Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Revenue of $345.1 million Net income of $12.9 million Adjusted EBITDA* of $2.7 million Fiscal Year 2026 Guidance Ranges: Revenue expected in a range of $1.650 billion to $1.750 billion Adjusted EBITDA* expected in a range of $120 million to $150 million Fourth Quarter Fiscal Year 2025 – Segment Highlights Senior Revenue of $82.5 million Adjusted EBITDA* of $7.7 million Approved Medicare Advantage policies of 85,344 Healthcare Services Revenue of $214.0 million Adjusted EBITDA* of $11.9 million 108,018 SelectRx members Life Revenue of $48.0 million Adjusted EBITDA* of $6

    8/21/25 7:30:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    1/29/24 3:26:24 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    2/14/23 1:42:28 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    2/1/23 4:54:05 PM ET
    $SLQT
    Specialty Insurers
    Finance